Circadin®, prolonged-release melatonin, provides good quality natural sleep for patients with primary insomnia, offering an effective and safe treatment for their sleep problems.
Data has shown that elderly patients suffering from primary insomnia secrete lower levels of melatonin than those with good sleep quality.
Circadin® patented formulation mimics the natural melatonin profile by releasing melatonin gradually over 8-10 hours, which results in re-setting of the natural circadian rhythms and restorative sleep (fig 1). Circadin® replaces the decreased melatonin levels so patients gain good sleep quality and subsequently improved daytime functioning. It is this unique profile that differentiates Circadin® from the currently available CNS-depressant hypnotics.
Circadin® is the first sleep agent to demonstrate positive effects on sleep quality, Quality of Life, and most importantly next day alertness and functioning1.
Circadin® is also effective in improving sleep latency2. In clinical trials the Circadin® has an excellent safety and tolerability profile with no obvious differences in safety parameters between active treatment and placebo group2. It has no negative effects on memory or rebound effects. Circadin® therefore provides insomnia patients with an effective treatment with a favorable safety and tolerability profile.
Circadin® was approved in Europe by the EMA in 2007 for the treatment of primary insomnia in patients aged 55 years and older. Due to the good safety and tolerability profile, Circadin® treatment was not limited to 2-4 weeks as classical sedative sleep drugs, and is allowed to be taken for up to 3 months without interruption.